<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">glazmag</journal-id><journal-title-group><journal-title xml:lang="ru">The EYE ГЛАЗ</journal-title><trans-title-group xml:lang="en"><trans-title>The EYE GLAZ</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2222-4408</issn><issn pub-type="epub">2686-8083</issn><publisher><publisher-name>Академия медицинской оптики и оптометрии</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33791/2222-4408-2023-3-244-251</article-id><article-id custom-type="elpub" pub-id-type="custom">glazmag-474</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРАКТИКУМ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>WORKSHOP</subject></subj-group></article-categories><title-group><article-title>Диабетическая ретинопатия в практике оптометриста</article-title><trans-title-group xml:lang="en"><trans-title>Diabetic retinopathy in the practice of an optometrist</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сотникова</surname><given-names>Ю. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Sotnikova</surname><given-names>Yu. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сотникова Юлия Петровна, врач-офтальмолог высшей категории, ведущий специалист</p><p>121205, г. Москва, Большой бульвар, д. 46, стр. 1</p></bio><bio xml:lang="en"><p>Yulia P. Sotnikova, Ophthalmologist of the Highest Category, Leading Specialis</p><p>46, bld. 1, Bolshoy Boulevard, Moscow, 121205</p></bio><email xlink:type="simple">juliasot0509@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лоскутов</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Loskutov</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лоскутов Игорь Анатольевич, доктор медицинских наук, главный офтальмолог Московской области, руководитель офтальмологической службы, заведующий научным отделом и кафедрой офтальмологии и оптометрии</p><p>129090, г. Москва, пр. Мира, д. 61/2</p></bio><bio xml:lang="en"><p>Igor A. Loskutov, Dr. Sci. (Med.), Ophthalmologist, Chief Ophthalmologist of the Moscow Region, Head of the Ophthalmological Service, Head of the Scientific Department and Department of Ophthalmology and Optometry</p><p>61/2, Mira Ave., Moscow, 129090</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сотников</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Sotnikov</surname><given-names>D. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сотников Дмитрий Сергеевич, начальник терапевтического отделения медицинского отряда</p><p>194044, г. Санкт-Петербург, ул. Академика Лебедева, д. 6ж</p></bio><bio xml:lang="en"><p>Dmitry S. Sotnikov, Head of the Therapeutic Department of the Medical Detachment</p><p>6g, Akademika Lebedeva Str., Saint-Petersburg, 194044</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пирятинский</surname><given-names>Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Piryatinsky</surname><given-names>B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пирятинский Борис, кандидат медицинских наук, ведущий хирург глазного отделения</p><p>4941492, г. Петах-Тиква, ул. Жаботинского, д. 39</p></bio><bio xml:lang="en"><p>Boris Piryatinsky, Сand. Sci. (Med.), Ophthalmologist, Leading surgeon</p><p>39, Jabotinsky Str., Petah-Tikva, 4941492</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Многопрофильный медицинский центр «Хадасса Медикал ЛТД»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Multidisciplinary Medical Center «Hadassah Medical LTD»</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ Минздрава Московской области «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>MONICA named after Vladimirsky M.F.</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kirov Military Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Медицинский центр им. Рабина</institution><country>Израиль</country></aff><aff xml:lang="en"><institution>Rabin Medical Center</institution><country>Israel</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>29</day><month>09</month><year>2023</year></pub-date><volume>25</volume><issue>3</issue><fpage>244</fpage><lpage>251</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Академия медицинской оптики и оптометрии, 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Академия медицинской оптики и оптометрии</copyright-holder><copyright-holder xml:lang="en">Академия медицинской оптики и оптометрии</copyright-holder><license xlink:href="https://www.theeyeglaz.com/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://www.theeyeglaz.com/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://www.theeyeglaz.com/jour/article/view/474">https://www.theeyeglaz.com/jour/article/view/474</self-uri><abstract><p>Диабетическая ретинопатия – это микроангиопатия, возникающая в результате хронического длительного воздействия высокого уровня глюкозы на сетчатку глаз. В оптометрической практике специалист, с одной стороны, сталкивается с невозможностью проведения полной коррекции зрения, а с другой, может оказаться первым, кто заподозрит такую патологию и направит пациента к врачу. При этом следует отметить, что медицинские работники, специализирующиеся на лечении диабета, часто работают изолированно, что требует от пациентов посещения нескольких клиник и врачей. Несмотря на большую актуальность, во многих странах сохраняются сложности координации программ лечения узкопрофильными специалистами, которые оказывают помощь людям, живущим с сахарным диабетом. В этой статье мы обсуждаем эпидемиологию диабетической ретинопатии, описываем подход к ее оценке, диагностике и представляем обзор принципов лечения. В статье упоминается большое число лиц с диабетической ретинопатией в мире, и в том числе в России, и отмечается, что фактическая распространенность, вероятно, выше, чем сообщаемые цифры.</p></abstract><trans-abstract xml:lang="en"><p>Diabetic retinopathy is a microangiopathy that occurs as a result of chronic prolonged exposure to high glucose levels on the retina of the eyes. In optometric practice, a specialist, on the one hand, faces the impossibility of performing a complete correction of vision, and on the other, may be the first to suspect such a pathology and refer the patient to a doctor. At the same time, it should be noted that medical professionals specializing in the treatment of diabetes often work in isolation, which requires patients to visit several clinics and specialists. Despite the great relevance, in many countries, difficulties remain in coordinating treatment programs for narrow-profile specialists who provide assistance to people living with diabetes. In this article we discuss the epidemiology, describe an approach to its assessment, diagnosis and provide an overview of the principles of treatment of diabetic retinopathy. In this article we discuss the epidemiology and natural history of diabetic retinopathy and describe an approach to its assessment, diagnosis and provide an overview of the principles of treatment of diabetic retinopathy. The article mentions a large number of people with diabetic retinopathy in the world, including in Russia, and notes that the actual prevalence is probably higher than the reported figures.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>диабетическая ретинопатия</kwd><kwd>диабетический макулярный отек</kwd><kwd>лазерная фотокоагуляция</kwd><kwd>интравитреальные инъекции</kwd><kwd>витрэктомия</kwd><kwd>биогенные пептиды</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diabetic retinopathy</kwd><kwd>diabetic macular edema</kwd><kwd>laser photocoagulation</kwd><kwd>intravitreal injections</kwd><kwd>vitrectomy</kwd><kwd>biogenic peptides</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Fung T.H., Patel B., Wilmot E.G., Amoaku W.M. Diabetic retinopathy for the non-ophthalmologist. Clin Med (Lond). 2022;22(2):112–116. https://doi.org/10.7861/clinmed.2021-0792</mixed-citation><mixed-citation xml:lang="en">Fung T.H., Patel B., Wilmot E.G., Amoaku W.M. Diabetic retinopathy for the non-ophthalmologist. Clin Med (Lond). 2022;22(2):112–116. https://doi.org/10.7861/clinmed.2021-0792</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">GBD 2019 Blindness and Visual Impairment Collaborators. Causes of blindness and visual impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to vision 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:144–160. https://doi.org/10.1016/S2214-109X(20)30489-7</mixed-citation><mixed-citation xml:lang="en">GBD 2019 Blindness and Visual Impairment Collaborators. Causes of blindness and visual impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to vision 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:144–160. https://doi.org/10.1016/S2214-109X(20)30489-7</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Modjtahedi B.S., Wu J., Luong T.Q. et al. Severity of diabetic retinopathy and the risk of future cerebrovascular disease, cardiovascular disease, and all-cause mortality. Ophthalmology. 2021;128:1169–1179. https://doi.org/10.1016/j.oph-tha.2020.12.019</mixed-citation><mixed-citation xml:lang="en">Modjtahedi B.S., Wu J., Luong T.Q. et al. Severity of diabetic retinopathy and the risk of future cerebrovascular disease, cardiovascular disease, and all-cause mortality. Ophthalmology. 2021;128:1169–1179. https://doi.org/10.1016/j.oph-tha.2020.12.019</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Липатов Д.В., Викулова О.К., Железнякова А.В. и др. Эпидемиология диабетической ретинопатии в Российской Федерации по данным федерального регистра пациентов с сахарным диабетом. Сахарный диабет. 2018;21(4):230– 240. https://doi.org/10.14341/DM9797</mixed-citation><mixed-citation xml:lang="en">Lipatov D.V., Vikulova O.K., Zheleznyakova A.V. et al. Epidemiology of diabetic retinopathy in the Russian Federation according to the Federal register of patients with diabetes mellitus. Diabetes mellitus. 2018;21(4):230–240. https://doi.org/10.14341/DM9797</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.</mixed-citation><mixed-citation xml:lang="en">UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713.</mixed-citation><mixed-citation xml:lang="en">UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">The ACCORD Study Group, ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Eng J Med. 2010;363:233–244. https://doi.org/10.1056/NEJMoa1001288</mixed-citation><mixed-citation xml:lang="en">The ACCORD Study Group, ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Eng J Med. 2010;363:233–244. https://doi.org/10.1056/NEJMoa1001288</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Keech A.C., Mitchell P., Summanen P.A. et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687–1697. https://doi.org/10.1016/S0140-6736(07)61607-9</mixed-citation><mixed-citation xml:lang="en">Keech A.C., Mitchell P., Summanen P.A. et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687–1697. https://doi.org/10.1016/S0140-6736(07)61607-9</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology. 1978;85:82–106.</mixed-citation><mixed-citation xml:lang="en">The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology. 1978;85:82–106.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology. 1981;88:583–600.</mixed-citation><mixed-citation xml:lang="en">The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology. 1981;88:583–600.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98:766–785.</mixed-citation><mixed-citation xml:lang="en">Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98:766–785.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Weiter J.J., Zuckerman R. The influence of the photoreceptor-RPE complex on the inner retina. An explanation for the beneficial effects of photocoagulation. Ophthalmology. 1980;87:1133–1139.</mixed-citation><mixed-citation xml:lang="en">Weiter J.J., Zuckerman R. The influence of the photoreceptorRPE complex on the inner retina. An explanation for the beneficial effects of photocoagulation. Ophthalmology. 1980;87:1133–1139.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Machemer R., Blankenship G. Vitrectomy for proliferative diabetic retinopathy associated with vitreous haemorrhage. Ophthalmology. 1981;88:643–646.</mixed-citation><mixed-citation xml:lang="en">Machemer R., Blankenship G. Vitrectomy for proliferative diabetic retinopathy associated with vitreous haemorrhage. Ophthalmology. 1981;88:643–646.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Maturi R.K., Glassman A.R., Josic K. et al. Effect of intravitreous antivascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: The protocol W randomised clinical trial. JAMA Ophthalmol. 2021;139:701–712. https://doi.org/10.1001/jamaophthalmol.2021.0606</mixed-citation><mixed-citation xml:lang="en">Maturi R.K., Glassman A.R., Josic K. et al. Effect of intravitreous antivascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: The protocol W randomised clinical trial. JAMA Ophthalmol. 2021;139:701–712. https://doi.org/10.1001/jamaophthalmol.2021.0606</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sivaprasad S., Prevost A.T., Vasconcelos J.C. et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389:2193–2203. https://doi.org/10.1016/S0140-6736(17)31193-5</mixed-citation><mixed-citation xml:lang="en">Sivaprasad S., Prevost A.T., Vasconcelos J.C. et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389:2193–2203. https://doi.org/10.1016/S0140-6736(17)31193-5</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Schmidt-Erfurth U. et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185– 222. https://doi.org/10.1159/000458539</mixed-citation><mixed-citation xml:lang="en">Schmidt-Erfurth U. et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185– 222. https://doi.org/10.1159/000458539</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Егоров Е.А. Опыт применения Ретиналамина при различных офтальмологических заболеваниях. Клиническая офтальмология. 2017;18(1):35–38. https://doi.org/10.21689/2311-7729-2017-17-1-35-38</mixed-citation><mixed-citation xml:lang="en">Egorov E.A. Experience in the use of Retinalamine in various ophthalmic diseases. Clinical ophthalmology. 2017;18(1):35–38. https://doi.org/10.21689/2311-7729-2017-17-1-35-38</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Малышева Н.А., Россохин В.Ф. Применение ретиналамина на ранней стадии лечения непролиферативной диабетической ретинопатии у детей с сахарным диабетом 1 типа. Современные технологии в медицине. 2011;3:160–161.</mixed-citation><mixed-citation xml:lang="en">Malysheva N.A., Rossokhin V.F. The use of retinalamine at an early stage of treatment of non-proliferative diabetic retinopathy in children with type 1 diabetes mellitus. Modern technologies in medicine. 2011;3:160–161.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Верлов Н.А., Доротенко А.Р. и др. Исследование взаимодействия лиганд-рецептор и биораспределения лекарственного средства, содержащего полипептиды сетчатки крупного рогатого скота, при различных путях введения. Вестник офтальмологии. 2021;137(5):94–101. https://doi.org/10.17116/oftalma202113705194</mixed-citation><mixed-citation xml:lang="en">Verlov N.A., Dorotenko A.R. and coauthors. Investigation of the interaction of the ligand-reptor and the bio-distribution of the drug community supporting the polypeptides of the reticulum of group cattle, in the differentiation of communication routes. Vestnik Ophtalmology. 2021;137(5):94–101. https://doi.org/10.17116/oftalma202113705194</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Brownrigg J.R., Hughes C.O., Burleigh D. et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol. 2016;4(7):588–97. https://doi.org/10.1016/S2213-8587(16)30057-2</mixed-citation><mixed-citation xml:lang="en">Brownrigg J.R., Hughes C.O., Burleigh D. et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol. 2016;4(7):588–97. https://doi.org/10.1016/S2213-8587(16)30057-2</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Simó R., Ciudin A., Simó-Servat O. et al. Cognitive impairment and dementia: a new emerging complication of type 2 diabetes-The diabetologist’s perspective. Acta Diabetol. 2017;54(5):417–424. https://doi.org/10.1007/s00592-017-0970-5</mixed-citation><mixed-citation xml:lang="en">Simó R., Ciudin A., Simó-Servat O. et al. Cognitive impairment and dementia: a new emerging complication of type 2 diabetes-The diabetologist’s perspective. Acta Diabetol. 2017;54(5):417–424. https://doi.org/10.1007/s00592-017-0970-5</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
